[Familial hypophosphatemic rickets].
Identifieur interne : 000500 ( Main/Exploration ); précédent : 000499; suivant : 000501[Familial hypophosphatemic rickets].
Auteurs : G. Reusz [Hongrie]Source :
- Orvosi hetilap [ 0030-6002 ] ; 2001.
Descripteurs français
- KwdFr :
- Administration par voie orale (MeSH), Animaux (MeSH), Calcinose (MeSH), Hormone de croissance humaine (administration et posologie), Hormone de croissance humaine (effets indésirables), Humains (MeSH), Hypophosphatémie (diagnostic), Hypophosphatémie (génétique), Hypophosphatémie (métabolisme), Hypophosphatémie (thérapie), Metalloendopeptidases (génétique), Mutation (MeSH), Phosphates (administration et posologie), Phosphates (métabolisme), Rachitisme (génétique), Rachitisme (métabolisme), Rein (anatomopathologie), Rein (métabolisme).
- MESH :
- administration et posologie : Hormone de croissance humaine, Phosphates.
- anatomopathologie : Rein.
- diagnostic : Hypophosphatémie.
- effets indésirables : Hormone de croissance humaine.
- génétique : Hypophosphatémie, Metalloendopeptidases, Rachitisme.
- métabolisme : Hypophosphatémie, Phosphates, Rachitisme, Rein.
- thérapie : Hypophosphatémie.
- Administration par voie orale, Animaux, Calcinose, Humains, Mutation.
English descriptors
- KwdEn :
- Administration, Oral (MeSH), Animals (MeSH), Calcinosis (MeSH), Human Growth Hormone (administration & dosage), Human Growth Hormone (adverse effects), Humans (MeSH), Hypophosphatemia (diagnosis), Hypophosphatemia (genetics), Hypophosphatemia (metabolism), Hypophosphatemia (therapy), Kidney (metabolism), Kidney (pathology), Metalloendopeptidases (genetics), Mutation (MeSH), Phosphates (administration & dosage), Phosphates (metabolism), Rickets (genetics), Rickets (metabolism).
- MESH :
- chemical , administration & dosage : Human Growth Hormone, Phosphates.
- chemical , adverse effects : Human Growth Hormone.
- diagnosis : Hypophosphatemia.
- genetics : Hypophosphatemia, Metalloendopeptidases, Rickets.
- metabolism : Hypophosphatemia, Kidney, Phosphates, Rickets.
- pathology : Kidney.
- therapy : Hypophosphatemia.
- Administration, Oral, Animals, Calcinosis, Humans, Mutation.
Abstract
Familiar hypophosphatemic rickets (FHR) is characterized by isolated defect of renal phosphate reabsorption, hypophosphataemia, rickets and poor growth. In untreated cases parathyroid hormone and calcitriol levels are normal. FHR is caused by mutations of the PHEX gene encoding a zinc-binding metalloprotease enzyme. PHEX is expressed in bones and the parathyroid gland but not in the kidney. The gene product is involved in the inactivation of a phosphate regulating hormone (phosphatonin). The presence of this hormone through unknown mechanisms decreases the sodium-dependent phosphate cotransporter in the kidney resulting in impaired phosphate transport. In addition the PHEX gene product exerts autocrine and paracrine effects on the bone. Despite recent advances in the understanding of the pathomechanism, treatment of FHR is still symptomatic. It consists of active vitamin D analogues and oral phosphate supplementation. Nephrocalcinosis is a well-known, usually non-progressive side effect of the conventional therapy. As shown by pilot studies, poorly growing children with FHR may benefit from the positive effect of human recombinant growth hormone (rhGH). However, rhGH treatment could aggravate the already existing tendency to disproportionate growth resulting in the overgrowth of the trunk. The disturbed phosphate homeostasis persists during the whole life span of the FHR patients. It is therefore essential to provide lifelong care, to prevent late skeletal and dental consequences or to treat them if already established. That care should be done by the teamwork of the pediatrician, internist, orthopedist, dentist and the psychologist.
PubMed: 11778363
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Familial hypophosphatemic rickets].</title><author><name sortKey="Reusz, G" sort="Reusz, G" uniqKey="Reusz G" first="G" last="Reusz">G. Reusz</name><affiliation wicri:level="3"><nlm:affiliation>Altalános Orvostudományi Kar, I. sz. Gyermekklinika, Semmelweis Egyetem, Budapest. reusz@gyer1.sote.hu</nlm:affiliation><country>Hongrie</country><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName><wicri:orgArea>Altalános Orvostudományi Kar, I. sz. Gyermekklinika, Semmelweis Egyetem</wicri:orgArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11778363</idno><idno type="pmid">11778363</idno><idno type="wicri:Area/Main/Corpus">000507</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000507</idno><idno type="wicri:Area/Main/Curation">000507</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000507</idno><idno type="wicri:Area/Main/Exploration">000507</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Familial hypophosphatemic rickets].</title><author><name sortKey="Reusz, G" sort="Reusz, G" uniqKey="Reusz G" first="G" last="Reusz">G. Reusz</name><affiliation wicri:level="3"><nlm:affiliation>Altalános Orvostudományi Kar, I. sz. Gyermekklinika, Semmelweis Egyetem, Budapest. reusz@gyer1.sote.hu</nlm:affiliation><country>Hongrie</country><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName><wicri:orgArea>Altalános Orvostudományi Kar, I. sz. Gyermekklinika, Semmelweis Egyetem</wicri:orgArea></affiliation></author></analytic><series><title level="j">Orvosi hetilap</title><idno type="ISSN">0030-6002</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral (MeSH)</term><term>Animals (MeSH)</term><term>Calcinosis (MeSH)</term><term>Human Growth Hormone (administration & dosage)</term><term>Human Growth Hormone (adverse effects)</term><term>Humans (MeSH)</term><term>Hypophosphatemia (diagnosis)</term><term>Hypophosphatemia (genetics)</term><term>Hypophosphatemia (metabolism)</term><term>Hypophosphatemia (therapy)</term><term>Kidney (metabolism)</term><term>Kidney (pathology)</term><term>Metalloendopeptidases (genetics)</term><term>Mutation (MeSH)</term><term>Phosphates (administration & dosage)</term><term>Phosphates (metabolism)</term><term>Rickets (genetics)</term><term>Rickets (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale (MeSH)</term><term>Animaux (MeSH)</term><term>Calcinose (MeSH)</term><term>Hormone de croissance humaine (administration et posologie)</term><term>Hormone de croissance humaine (effets indésirables)</term><term>Humains (MeSH)</term><term>Hypophosphatémie (diagnostic)</term><term>Hypophosphatémie (génétique)</term><term>Hypophosphatémie (métabolisme)</term><term>Hypophosphatémie (thérapie)</term><term>Metalloendopeptidases (génétique)</term><term>Mutation (MeSH)</term><term>Phosphates (administration et posologie)</term><term>Phosphates (métabolisme)</term><term>Rachitisme (génétique)</term><term>Rachitisme (métabolisme)</term><term>Rein (anatomopathologie)</term><term>Rein (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Human Growth Hormone</term><term>Phosphates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Human Growth Hormone</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hormone de croissance humaine</term><term>Phosphates</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Rein</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hypophosphatemia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hypophosphatémie</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hormone de croissance humaine</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hypophosphatemia</term><term>Metalloendopeptidases</term><term>Rickets</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hypophosphatémie</term><term>Metalloendopeptidases</term><term>Rachitisme</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Hypophosphatemia</term><term>Kidney</term><term>Phosphates</term><term>Rickets</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hypophosphatémie</term><term>Phosphates</term><term>Rachitisme</term><term>Rein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Kidney</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hypophosphatemia</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Hypophosphatémie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Calcinosis</term><term>Humans</term><term>Mutation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Animaux</term><term>Calcinose</term><term>Humains</term><term>Mutation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Familiar hypophosphatemic rickets (FHR) is characterized by isolated defect of renal phosphate reabsorption, hypophosphataemia, rickets and poor growth. In untreated cases parathyroid hormone and calcitriol levels are normal. FHR is caused by mutations of the PHEX gene encoding a zinc-binding metalloprotease enzyme. PHEX is expressed in bones and the parathyroid gland but not in the kidney. The gene product is involved in the inactivation of a phosphate regulating hormone (phosphatonin). The presence of this hormone through unknown mechanisms decreases the sodium-dependent phosphate cotransporter in the kidney resulting in impaired phosphate transport. In addition the PHEX gene product exerts autocrine and paracrine effects on the bone. Despite recent advances in the understanding of the pathomechanism, treatment of FHR is still symptomatic. It consists of active vitamin D analogues and oral phosphate supplementation. Nephrocalcinosis is a well-known, usually non-progressive side effect of the conventional therapy. As shown by pilot studies, poorly growing children with FHR may benefit from the positive effect of human recombinant growth hormone (rhGH). However, rhGH treatment could aggravate the already existing tendency to disproportionate growth resulting in the overgrowth of the trunk. The disturbed phosphate homeostasis persists during the whole life span of the FHR patients. It is therefore essential to provide lifelong care, to prevent late skeletal and dental consequences or to treat them if already established. That care should be done by the teamwork of the pediatrician, internist, orthopedist, dentist and the psychologist.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11778363</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2009</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0030-6002</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>48</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Orvosi hetilap</Title><ISOAbbreviation>Orv Hetil</ISOAbbreviation></Journal><ArticleTitle>[Familial hypophosphatemic rickets].</ArticleTitle><Pagination><MedlinePgn>2659-65</MedlinePgn></Pagination><Abstract><AbstractText>Familiar hypophosphatemic rickets (FHR) is characterized by isolated defect of renal phosphate reabsorption, hypophosphataemia, rickets and poor growth. In untreated cases parathyroid hormone and calcitriol levels are normal. FHR is caused by mutations of the PHEX gene encoding a zinc-binding metalloprotease enzyme. PHEX is expressed in bones and the parathyroid gland but not in the kidney. The gene product is involved in the inactivation of a phosphate regulating hormone (phosphatonin). The presence of this hormone through unknown mechanisms decreases the sodium-dependent phosphate cotransporter in the kidney resulting in impaired phosphate transport. In addition the PHEX gene product exerts autocrine and paracrine effects on the bone. Despite recent advances in the understanding of the pathomechanism, treatment of FHR is still symptomatic. It consists of active vitamin D analogues and oral phosphate supplementation. Nephrocalcinosis is a well-known, usually non-progressive side effect of the conventional therapy. As shown by pilot studies, poorly growing children with FHR may benefit from the positive effect of human recombinant growth hormone (rhGH). However, rhGH treatment could aggravate the already existing tendency to disproportionate growth resulting in the overgrowth of the trunk. The disturbed phosphate homeostasis persists during the whole life span of the FHR patients. It is therefore essential to provide lifelong care, to prevent late skeletal and dental consequences or to treat them if already established. That care should be done by the teamwork of the pediatrician, internist, orthopedist, dentist and the psychologist.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reusz</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Altalános Orvostudományi Kar, I. sz. Gyermekklinika, Semmelweis Egyetem, Budapest. reusz@gyer1.sote.hu</Affiliation></AffiliationInfo></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Familiaris hypophosphataemiás rachitis.</VernacularTitle></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Orv Hetil</MedlineTA><NlmUniqueID>0376412</NlmUniqueID><ISSNLinking>0030-6002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010710">Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>12629-01-5</RegistryNumber><NameOfSubstance UI="D019382">Human Growth Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002114" MajorTopicYN="N">Calcinosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019382" MajorTopicYN="N">Human Growth Hormone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017674" MajorTopicYN="N">Hypophosphatemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008666" MajorTopicYN="N">Metalloendopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012279" MajorTopicYN="N">Rickets</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>41</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11778363</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Hongrie</li></country><region><li>Hongrie centrale</li></region><settlement><li>Budapest</li></settlement></list><tree><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Reusz, G" sort="Reusz, G" uniqKey="Reusz G" first="G" last="Reusz">G. Reusz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000500 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000500 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11778363
|texte= [Familial hypophosphatemic rickets].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11778363" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |